Introducing CVD StripAssay T

Cardiovascular Diseases (CVD) are pervasive but often preventable. Atherosclerosis and venous thrombosis stand as two major manifestations of CVD, influenced by intricate interplays between genetics and environment. Unhealthy lifestyles combined with specific genetic variants can heighten atherosclerosis risk, encompassing genes involved in endothelial function, hyperlipidemia, hypertension, and inflammation.

Similarly, a blend of adverse factors like hormone intake, immobilization, surgery, or cancer, coupled with genetic variations in coagulation genes, can trigger venous thrombosis. The significance of testing for genetic variations and instituting proper prophylaxis cannot be overstated, contributing to reduced CVD risks.

The CVD StripAssay T  primarily targets Factor V (FV) mutations, making it a pivotal tool in assessing thrombophilia risk:

1. FV Leiden (1691G>A; R506Q): A significant genetic risk factor for inherited thrombophilia, leading to activated protein C resistance, impacting 20-50% of VTE patients.
2. FV R2 haplotype (H1299R): A mild risk factor for thrombosis, increasing CVD risk in FV Leiden carriers.
3. Prothrombin (PTH; Factor II) 20210G>A: Carriers exhibit a threefold elevated risk for cerebral and deep vein thrombosis, significantly escalating when combined with FV Leiden. The A allele elevates prothrombin levels.
4. 5,10-Methylenetetrahydrofolate Reductase (MTHFR):
   • MTHFR 677C>T: Homozygosity predisposes to arterial and venous thrombosis in the presence of additional risk factors.
   • MTHFR 1298A>C: Compound heterozygosity for 677C>T and 1298A>C associates with reduced MTHFR enzyme activity.
5. Factor XIII (FXIII) V34L: The L variant offers protection against VTE.
6. Plasminogen Activator Inhibitor 1 (PAI-1, Serpin E1) 4G/5G: The 4G allele correlates with higher PAI-1 transcription rates, considered a risk factor for VTE, MI, and early pregnancy loss.
7. Endothelial Protein C Receptor (EPCR):
   • EPCR 4600A>G (A3 haplotype): Carriers predisposed to VTE and fetal loss due to elevated soluble EPCR plasma levels.
   • EPCR 4678G>C (A1 haplotype): Homozygous A1 exerts a protective effect in FV Leiden carriers.

The CVD StripAssay T offers a solution for precise diagnostics, comprising essential components for efficient testing. The assay covers nine key mutations associated with cardiovascular disease, enhancing early intervention prospects and patient care.

Conclusion

The CVD StripAssay T by ViennaLab represents is a tool for assessing genetic factors contributing to atherosclerosis and thrombosis risks. By targeting pivotal mutations, it helps healthcare professionals to make informed decisions and initiate timely prophylactic measures, reducing the burden of CVD.